Pfizer/BioNTech Claims Their COVID-19 Vaccine is 90% Effective

Pfizer and partner BioNTech announced that their vaccine against COVID-19 was 90% effective according to their phase 3 trials.

Pfizer and partner BioNTech announced that their vaccine against COVID-19 was 90% effective according to their phase 3 trials.

The Pfizer/BioNTech vaccine is the first to be tested in the United States to generate late-stage data from their Phase III testing. 

The Pfizer/BioNTech tests involved two injections of the vaccine three weeks apart where 94 test subjects experienced more than 90% fewer cases of symptomatic COVID-19 than those who received a placebo.

“The first set of results from our Phase III COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,”  said Pfizer chairman and CEO Albert Bourla.

According to the Pfizer/BioNTech researchers, they found no serious safety concerns associated with the vaccine and believed that the immunizing effects will last a long time. 

“We should be more optimistic that the immunization effect can last for at least a year,” said BioNTech’s CEO Ugur Sahin.

Pfizer/BioNTech will not file for an emergency use authorization to distribute the vaccine until half of the patients in their study have been observed for any safety issues in accordance with Food and Drug Administration (FDA) standards. 

Presently, there is no key information about the vaccine available and no information yet on whether the vaccine prevents severe COVID infection.

Editors Note: There was a headline formatting issue In the story “EFFECTIVE-COVID-VACCINE” sent at: 09.11.2020 08:54.

This is a corrected repeat.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.